Belsomra (Suvorexant) Cost in Nevada: Prices, Insurance, and Savings in 2026

Suvorexant is the generic name for the brand-name insomnia medication Belsomra, an oral dual orexin receptor antagonist (DORA) made by Merck. The FDA approved suvorexant in August 2014 for adults with insomnia involving difficulty falling asleep, staying asleep, or both, at doses generally ranging from 5 mg to 20 mg taken at bedtime (per FDA approval records). It is a Schedule IV controlled substance and, as of this review, no FDA-approved generic version exists, so every Nevada patient is paying for a brand-only drug rather than a generic.

Belsomra's manufacturer list price (wholesale acquisition cost) has been reported publicly in the range of a few hundred dollars per 30-day supply, but list price is not what most people pay. Actual out-of-pocket cost in Nevada depends heavily on three variables: whether a commercial insurer or Medicaid covers it, whether a manufacturer savings card or a discount card is used, and whether the patient chooses brand Belsomra versus a compounded suvorexant preparation from a licensed pharmacy. Because pharmacy cash prices and plan copays change frequently and vary by pharmacy chain and zip code, the specific dollar figures below should be treated as illustrative ranges that need a same-day check against a Nevada pharmacy or insurer, not as fixed prices.

The direct answer

Belsomra is a brand-only, Schedule IV prescription sleep medication with no generic equivalent available in the United States as of 2026. Nevada Medicaid has historically excluded newer brand insomnia drugs like Belsomra from its preferred drug list in favor of generic zolpidem, eszopiclone, and trazodone, so Medicaid patients typically need a prior authorization with documented failure of a preferred agent. Commercially insured patients often pay far less than the list price through formulary tiering, a manufacturer copay card, or a pharmacy discount card, while cash-pay patients without any of those tools can face several hundred dollars per month. Anyone comparing numbers should confirm the current price and coverage rule directly with the pharmacy or plan, since these figures move month to month.

What you can rely on without checking, and what you cannot

Stable and verifiable now:

• Suvorexant/Belsomra's FDA-approved indication (insomnia, sleep onset and/or maintenance), its drug class (DORA), and its Schedule IV controlled-substance status.
• That no FDA-approved generic suvorexant exists as of this review; that fact can change once a manufacturer receives approval, so it should be re-checked periodically.
• That the American Academy of Sleep Medicine's clinical practice guideline lists suvorexant as one option among several pharmacologic treatments for chronic insomnia in adults, distinct from an FDA indication, a guideline recommendation reflects expert synthesis of trial evidence, not a regulatory approval.
• That 503A compounding pharmacies operating under state board of pharmacy licensure and USP <795> non-sterile compounding standards may prepare patient-specific suvorexant formulations when a prescriber documents a clinical need (for example, a strength that is not commercially manufactured, or difficulty swallowing tablets). Compounded drugs are not FDA-approved products; they are not required to demonstrate the same bioequivalence testing as an approved generic, and quality depends on the compounding pharmacy's sourcing and accreditation.
• That FDA added boxed warnings in 2019 to certain sedative-hypnotics (zolpidem, eszopiclone, zaleplon) for rare complex sleep behaviors; suvorexant works through a different mechanism (blocking orexin signaling rather than broadly enhancing GABA activity), which is a mechanistic distinction, not a guarantee of a better safety profile in every patient.

Volatile, plan-specific, or unverified in this review, confirm before relying on them:

• Any specific cash price, insurer copay, Medicaid prior-authorization outcome, employer-plan rule, or discount-card price named for Nevada. Pharmacy cash prices can differ by more than $100 between two pharmacies in the same city, and insurer tiering changes at least annually with new plan years.
• The manufacturer savings card's exact copay floor and annual cap, since manufacturer coupon terms are updated periodically and are not usable with any government-funded insurance (Medicare, Medicaid, Tricare).
• Any specific compounding-pharmacy price, since compounded suvorexant pricing is set independently by each 503A pharmacy and is not standardized.
• Precise trial statistics (exact percentage improvements, adverse-event rates, or number-needed-to-treat figures) attributed to specific studies. The original pivotal trials and later meta-analyses do show suvorexant outperforming placebo on sleep-onset and sleep-maintenance measures, with next-day somnolence as the most commonly reported side effect, but exact figures should be pulled from the primary publication rather than repeated from a secondary summary.

Is Belsomra covered by Nevada Medicaid?

Nevada Medicaid's pharmacy benefit, like most state Medicaid programs, maintains a preferred drug list that favors older, lower-cost generic hypnotics (zolpidem, eszopiclone, trazodone) over newer brand-only agents such as Belsomra. Getting a non-preferred brand covered typically requires a prior authorization, and PA approval for a brand sleep aid usually depends on documented trial and failure (or a contraindication) with at least one preferred generic first. Approval is not guaranteed even after that documentation is submitted. Because Medicaid formularies and PA criteria are reviewed and revised on a regular schedule, a Nevada Medicaid enrollee should confirm current Belsomra status and PA requirements directly with the state's pharmacy benefit manager or their managed care organization rather than assuming last year's rule still applies.

Does commercial insurance cover Belsomra in Nevada, and what will it cost?

Commercial plan coverage for Belsomra varies by carrier, metal tier, and specific employer plan design, and Nevada is no exception. In general, brand-name sleep medications without a generic equivalent are placed on a higher formulary tier (commonly "preferred brand" or "non-preferred brand"), which usually means a higher copay or coinsurance than a generic, and many plans require prior authorization showing that a generic hypnotic was tried first. Large Nevada employers and the state's own employee benefit plans set their own formularies and step-therapy rules, and these are updated at each new plan year. Rather than relying on a general estimate, a patient should call the number on the back of their insurance card, ask specifically whether Belsomra (suvorexant) is on the formulary, what tier it sits on, and whether prior authorization or step therapy applies for the current plan year.

Manufacturer and pharmacy discount programs

Merck has offered a Belsomra savings card program for commercially insured patients that reduces the copay, with exclusions for anyone enrolled in Medicare, Medicaid, Tricare, or another government-funded program, this is standard for manufacturer copay cards generally, since federal health care programs restrict their use as an anti-kickback safeguard. Independent discount platforms (for example GoodRx-type services) can also lower the cash price at chain pharmacies for patients without insurance coverage for the drug, though the size of the discount depends on the pharmacy and changes over time. Patient assistance programs offered by the manufacturer, or independent charitable programs, may provide free medication to qualifying low-income, uninsured patients. Anyone relying on a specific dollar figure from a savings card or discount platform should confirm the current terms on the program's own site or with the pharmacist at the time of fill, since these terms are not fixed.

Can a Nevada pharmacy compound suvorexant, and is that a real cost-saving option?

Yes, under Nevada's pharmacy practice regulations a licensed 503A compounding pharmacy may prepare suvorexant for an individual patient with a valid, patient-specific prescription when there is a documented clinical reason a commercially available product will not work (a strength that is not manufactured, a swallowing difficulty, or an allergy to an inactive ingredient, for example). Compounded medications are not FDA-approved and do not go through the same premarket testing as the branded product, so quality depends on the individual pharmacy's sourcing and process controls. Patients considering this route should ask specifically whether the pharmacy holds a recognized pharmacy compounding accreditation, request its Nevada Board of Pharmacy license number, and ask how it verifies the purity of the bulk suvorexant it uses. Compounded suvorexant is often less expensive than brand Belsomra, but the actual price is set independently by each pharmacy and is not something that can be quoted reliably at a state level.

Can you get a Belsomra prescription through telehealth in Nevada?

Telehealth prescribing of controlled substances, including Schedule IV drugs like suvorexant, is governed by a combination of federal DEA rules and state telehealth law, both of which have been in active revision in recent years following pandemic-era flexibilities. In general, a Nevada-licensed prescriber can evaluate a patient by real-time audio-video visit and prescribe suvorexant electronically if state and federal requirements at the time of the visit are met. Because the federal rules on prescribing controlled substances via telehealth without a prior in-person visit have changed more than once in recent years and remain an area to watch, a patient or clinician should confirm the current federal and Nevada-specific requirement before relying on a telehealth-only pathway, rather than assuming the rule that applied last year still applies.

How Belsomra compares with other insomnia medications on cost

Generic hypnotics, zolpidem, eszopiclone, and trazodone used off-label for sleep, are substantially less expensive than any brand DORA because they have long-established generic competition. The other two branded DORAs on the market, lemborexant (Dayvigo) and daridorexant (Quviviq), are also brand-only and priced in a broadly similar range to Belsomra; formulary placement and coupon availability, not the underlying mechanism, usually drive the practical price difference a patient sees at the counter. The clinical reason a prescriber might choose a DORA over an older benzodiazepine-receptor-agonist hypnotic is a different mechanism of action and a different side-effect profile (DORAs are not implicated in the same boxed warning for complex sleep behaviors that applies to zolpidem, eszopiclone, and zaleplon), not necessarily superior overall efficacy, that tradeoff is a clinical decision that should be made with a prescriber based on individual history, not from a price comparison alone.

Verification checklist: stable facts versus facts you must re-check today

Evidence boundary

Established: suvorexant's FDA approval, its mechanism as a dual orexin receptor antagonist, its Schedule IV status, the absence of an approved generic as of this review, and the general existence of guideline support, Medicaid preferred-drug-list structures, manufacturer savings cards, and 503A compounding pathways.

Plausible but not confirmed here: the specific dollar figures for Nevada cash prices, insurer copays, compounding-pharmacy prices, and savings-card terms cited in earlier versions of pricing pages like this one, these require direct, current verification and are not treated as established facts in this draft.

Not established from the material available: any claim about a named Nevada Medicaid managed care organization's specific approval rate, a named employer plan's exact 2025-2026 formulary rule, or exact clinical-trial percentages and p-values, none of which could be confirmed against a verified primary source in this review.

Common questions

Does Belsomra have a generic yet? No FDA-approved generic suvorexant exists as of this review. That status should be re-checked, since generic approval would change the cost picture substantially.

Is compounded suvorexant the same as brand Belsomra? No. It is a pharmacist-prepared, patient-specific formulation that has not gone through FDA premarket approval or the bioequivalence testing generics require. It may be appropriate for a documented clinical reason (a needed strength or form that is not commercially available), but it carries different quality assurance than the approved product.

Will Nevada Medicaid cover Belsomra? Historically, no, not on the preferred drug list; coverage typically requires a prior authorization after failing a preferred generic, and even then approval is not automatic. Confirm current criteria with Nevada Medicaid's pharmacy benefit manager.

Is a manufacturer savings card usable with Medicaid or Medicare? No. Manufacturer copay cards are generally restricted to commercially insured patients and are not usable with federal or state government health programs.

When should a sleep problem be evaluated urgently rather than managed with a hypnotic alone? Sudden severe insomnia with chest pain, shortness of breath, confusion, suicidal thoughts, or signs of a breathing-related sleep disorder (loud gasping, witnessed pauses in breathing) warrants prompt medical evaluation rather than a self-directed medication decision, regardless of cost considerations.

References

This article summarizes general regulatory, guideline, and pricing-structure information for Belsomra (suvorexant) in Nevada. It is not individualized medical or insurance advice. Specific prices, coverage rules, and telehealth prescribing rules referenced above change frequently and should be confirmed with a pharmacy, insurer, or licensed prescriber before making a treatment or purchasing decision.